Mallinck­rodt to spin off gener­ics busi­ness; Be­yond­Spring ready to sub­mit ap­proval for lead drug in Chi­na

→ Bare­ly a month af­ter Mallinck­rodt $MNK re­port­ed a key drug fail­ure, the com­pa­ny on Thurs­day said it was spin­ning off its spe­cial­ty gener­ics busi­ness — in­clud­ing Ami­ti­za which it gained from its $1.2 bil­lion ac­qui­si­tion of Su­cam­po — about two years af­ter the UK-based com­pa­ny first said it was seek­ing op­tions for the busi­ness. The gener­ics busi­ness, which ac­count­ed for just over a quar­ter of net sales last year, will re­tain the Mallinck­rodt name and be run by cur­rent CFO Matthew Har­baugh. The spe­cial­ty brand­ed drugs busi­ness, which in­cludes the con­tro­ver­sial drug Ac­thar, will be led by CEO Mark Trudeau, and will al­so be pub­licly list­ed un­der a so-far unan­nounced name.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.